)
Mersana Therapeutics (MRSN) investor relations material
Mersana Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Entered into a definitive merger agreement with Day One Biopharmaceuticals, Inc. on November 12, 2025, for $25.00 per share in cash plus contingent value rights up to $30.25 per share, totaling up to $285 million, with closing expected by end of January 2026.
Strategic restructuring in May 2025 reduced workforce by 55%, eliminated internal pipeline development, and focused R&D on breast cancer for lead candidate Emi-Le.
Ongoing clinical trials for lead candidates Emi-Le (B7-H4-targeting/XMT-1660) and XMT-2056, with encouraging interim data and resumed enrollment after FDA hold lifted.
Achieved a $15 million milestone payment from GSK for XMT-2056 development in Q3 2025; collaborations with Johnson & Johnson and Merck KGaA progressing.
Financial highlights
Collaboration revenue for Q3 2025 was $11.0 million, down from $12.6 million in Q3 2024; nine-month revenue was $16.8 million, down from $24.1 million year-over-year.
Net loss for Q3 2025 was $7.5 million ($1.51 per share), improved from $11.5 million ($2.34 per share) in Q3 2024; nine-month net loss was $56.0 million.
Cash and cash equivalents as of September 30, 2025, were $56.4 million, with capital resources expected to last into mid-2026.
Operating expenses and R&D expenses decreased year-over-year due to restructuring; R&D expense for Q3 2025 was $12.2 million.
Fully repaid $25 million in debt in July 2025, resulting in a $0.4 million loss on extinguishment.
Outlook and guidance
Current cash expected to fund operations into mid-2026; substantial doubt exists about ability to continue as a going concern if the merger is not completed.
Future funding needs may require additional equity, debt, or strategic transactions if acquisition does not close.
Focused near-term development on Emi-Le in breast cancer and continued dose escalation for XMT-2056.
Closing of the acquisition by Day One Biopharmaceuticals anticipated by end of January 2026, pending regulatory and shareholder approvals.
- Q2 2025 featured stable losses, pipeline progress, and a strengthened cash runway into mid-2026.MRSN
Q2 20253 Feb 2026 - Proprietary ADC platforms advance cancer therapy, supported by strong partnerships and cash runway.MRSN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Phase I ADC trials progress, costs fall, and $8M J&J milestone earned; cash runway into 2026.MRSN
Q2 20241 Feb 2026 - Clinical advances, milestone revenue, and cost controls narrowed Q3 net loss to $11.5M.MRSN
Q3 202414 Jan 2026 - Emi-Le achieved 23% ORR and strong tolerability in B7-H4 high, post-topo-1 ADC TNBC patients.MRSN
Study Update10 Jan 2026 - Lead ADC program shows 23% response in post-topo breast cancer; higher dose expansion planned.MRSN
Leerink Global Healthcare Conference 202526 Dec 2025 - Emi-Le shows 23% ORR in post-topo-1 TNBC, leading B7-H4 ADC class with strong cash position.MRSN
Q4 202426 Dec 2025 - B7-H4 ADC achieves 23% response in post-Topo TNBC, driving expansion and unique market positioning.MRSN
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - Innovative ADC shows strong efficacy and safety in B7-H4 positive cancers, with rapid development ahead.MRSN
Guggenheim SMID Cap Biotech Conference24 Dec 2025 - Annual meeting to vote on director elections, executive pay, auditor, and a reverse stock split.MRSN
Proxy Filing2 Dec 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage